Myfortic better for kidney patients -Novartis

ZURICH (Reuters) – Novartis said on Wednesday its Myfortic
transplant rejection treatment improved quality of life for
kidney transplant patients switching to the drug from
conventional treatments.

Novartis said a study showed that 66 percent of patients
who suffered gastrointestinal complaints while on a
conventional drug after surgery reported an improvement in
their symptoms when they switched to Myfortic.